

PANGENOMIC HEALTH INC.

Inaugural Annual Benefit Report

For the Financial Years Ended December 31, 2022 and 2021

As one of Canada's first publicly-traded benefit companies, we are very pleased to present our inaugural Annual Benefit Report (the "Report").

PanGenomic Health Inc. ("PanGenomic" or the "Company") became a benefit company under the laws of British Columbia on December 14, 2021, which means we committed formally in our Articles to conduct our business in a responsible and sustainable manner, and to promote one or more public benefits.

The public benefit selected by the Company is: *"to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual, as the Company's board of directors may from time to time determine to be appropriate."*

References in this Report to "we", "us" and "our" means the Company.

CONDUCT OF BUSINESS IN A RESPONSIBLE AND SUSTAINABLE MANNER

PanGenomic was founded to identify innovative technology solutions to help people identify the right natural solutions for conditions affecting their mental well-being. This foundation requires that our actions as a company be carried out responsibly and sustainably to demonstrate our positive intentions to the people we serve and the planet that produces plant-based remedies for healing.

PanGenomic is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company's initial focus is to support mental health. Our product suite includes the Nara app for personalized natural remedy information, the Mindleap app for wellness information and telehealth connection to practitioners and the MUJN diagnostic platform for clinical decision support.

We became a benefit company under the British Columbia *Business Corporations Act* (the "BCBCA") on December 14, 2021. Due to the close proximity of this change to the end of the fiscal year, we were not able undertake any significant activities towards our benefit commitments during the financial year ended December 31, 2021 other than to establish ourself as a benefit company.

During the financial year ended December 31, 2022, we made every effort to conduct our business responsibly and sustainably. As a technology company, our primary resource in our business is our staff. We recognize that for our business to succeed over the long term, we must

foster a work environment where each individual is respected and supported. We endeavour to provide maximum flexibility, enjoyment, financial reward and career growth opportunities for our employees.

Since our technology products promote plant-based solutions for healing, we also recognize that such use must be sustainable for the planet. The Plant Library used in our Nara consumer app incorporates evidence-based information about the health benefits of plants for people. This knowledge base serves to educate people about the value of plants with the hope that better care will be taken for plant species.

PROMOTION OF PUBLIC BENEFITS

As set out in our Articles, PanGenomic is committed to promoting and improving *“the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.”*

PanGenomic promoted public benefits associated with plant-based treatments for mental health conditions and alcohol use disorders by providing financial and non-financial support to the following organizations and their projects:

Psy Integrated Health Inc., a Benefit Corporation

[Psy Integrated Health](#) is a management services organisation stewarded by its community and health practitioners, created to accelerate the development of integrated health and transformational modalities. It provides specialised services to new and existing integrative community health clinics and organisations across North America, and operates the Empower Integrative Health Clinic in Vancouver, British Columbia. PanGenomic provided Psy Integrated with over \$35,000 in financial support and significant indirect support through staff hours for the below-referenced Sacred Circle Project.

Sacred Circle Project

The Sacred Circle project was initiated by the [Sacred Circle Indigenous Wellness Society](#), a not-for-profit organisation that promotes access for Indigenous People to health and wellness services based on Indigenous ways of knowing through advocacy, research, awareness, mentorship, and funding. The organisation comprises Indigenous community and spiritual leaders, business owners, professionals and those who have been directly affected by substance use disorder (“SUD”) from the Tsleil Waututh, Soowahlie, Tk'emlúps te Secwepemc, Cheam and other Sto:lo Nations located in British Columbia.

PanGenomic collaborated with Psy Integrated Health and [Thompson Rivers University](#) of Kamloops, BC, to support the Sacred Circle grant application made to the Canadian Institutes of Health Research (CIHR) for a substance use disorder study entitled, "A Phase 2, multisite, randomized controlled study evaluating the safety and efficacy of psilocybin-assisted psychotherapy for alcohol use disorder: Comparison of a culturally informed Indigenous setting to a Western therapy model for Indigenous individuals."

In addition to providing staff consulting services for the SUD grant application process at no cost, the Company offered free access to its NuStasis software for the proposed clinical trial. PanGenomic's NuStasis software is a secure clinical research data management platform that has been used to power prior clinical research programs, such as the CIHR-funded BC Ministry of Health's ActionADE Adverse Drug Event Compliance Reporting Project. It has also been used to power the ASDBase platform for the iTARGET project (Individualized Treatments for Autism Recovery using Genetic-Environment Targets), which is an interdisciplinary collaboration between UBC's Life Sciences Institute, Autism Spectrum Disorders-Canadian American Research Consortium, the Autism Spectrum Interdisciplinary Research Group, Western University Kilee Patchell Evans Autism Research Group, the Pacific Autism Family Centre, Personalized Medicine Initiative, and the BC Ministry of Children and Family Development.

The Horizons Center Public Benefit Corporation

Since 2007, New York-based [Horizons PBC](#) has helped the public understand the world of psychedelics. Each year Horizons PBC hosts "Perspectives on Psychedelics" at the New York Academy of Medicine, its flagship conference that is the largest and longest-running annual gathering of the psychedelic community in the world. Conferences include briefings and dialogues on recent and ongoing clinical research featuring psychedelic drugs and therapies. In 2022 Horizons PBC added an annual conference in Portland, Oregon. PanGenomic provided over \$30,000 in financial support to Horizons PBC to support its ongoing operations.

ASSESSMENT AGAINST THIRD-PARTY STANDARD

Third Party Standard

The BCBCA requires that benefit companies assess and report on their overall performance in conducting their business in a responsible and sustainable manner and in promoting the selected public benefits, against a "third-party standard". A "third-party standard" means a standard developed by a third-party standard setting body for defining, reporting and assessing (a) the overall performance of the benefit company in relation to its conducting business in a responsible and sustainable manner, and (b) the performance of the benefit company in relation to the public benefits specified in that benefit company's articles.

The Company has selected the GRI Standards issued by the [Global Sustainability Standards Board, a third-party standard-setting body](#). This Report relates to the two completed financial years in which the Company has been a benefit company under the BCBCA. This Report is the first Annual Benefit Report for which this standard has been selected and applied. The GRI Standards enable an organization to report information about its most significant impacts on the economy, environment, and people, including impacts on their human rights, and how it manages these impacts.

In particular, PanGenomic has selected the *GRI 416: Customer Health and Safety 2016* ("GRI 416") topic standard for reporting, as it addresses customer health and safety, including an organization's systematic efforts to address health and safety across the life cycle of a product or service, and its adherence to customer health and safety regulations and voluntary codes. As

PanGenomic matures from a start-up company, we intend to expand our annual reporting under the GRI Standards in order to better understand and manage our impact on people and society.

Assessment

In accordance with the materiality tests set out in *GRI 3: Material Topics 2021* (“GRI 3”), the Company has determined that GRI 416 is an appropriate topic standard to apply given the significant impact that PanGenomic's business model may have on people's health. The Company considered the positive and negative impacts that may occur when an individual acts on health-related information provided through its Nara, Mindleap and MUJN products.

The Company discloses the following information for the financial year ended December 31, 2022 in accordance with Disclosure 3-3 of GRI 3 and GRI 416:

Disclosure Requirements		Response
<i>GRI 3 Material Topics 2021</i>		
<i>3.3 (a)</i>	<i>Describe the actual and potential, negative and positive impacts on the economy, environment, and people, including impacts on their human rights.</i>	Our products (Nara, Mindleap and MUJN) are intended to provide evidence-based information about natural solutions to support better health. The Company recognizes that there may be positive or negative health outcomes for individuals that undertake regimens involving natural solutions.
<i>3.3 (b)</i>	<i>Report whether the organization is involved with the negative impacts through its activities or as a result of its business relationships, and describe the activities or business relationships.</i>	It is anticipated that an individual encountering negative health impacts will contact their health practitioner.

Disclosure Requirements		Response
3.3 (c)	<i>Describe its policies or commitments regarding the material topic.</i>	<p>The Company is committed to identifying only evidence-based information about natural solutions. Its scientific team is responsible for researching and curating articles about natural solutions.</p> <p>The Company adheres to regulatory requirements set by Health Canada and the US Food and Drug Administration, and pays particular attention to the regulatory framework for natural health products, dietary supplements and botanical drugs.</p>
3.3 (d)	<i>Describe actions taken to manage the topic and related impacts, including:</i>	
	<i>i. actions to prevent or mitigate potential negative impacts;</i>	<p>The Company includes written warnings in its products about potential negative impacts of natural solutions and includes written notices that professional medical advice should be sought before consuming any natural health products. References to emergency hotline numbers in North America are also included in the Company's products.</p>

Disclosure Requirements		Response
	<i>ii. actions to address actual negative impacts, including actions to provide for or cooperate in their remediation;</i>	The Company is unable to address actual negative impacts sustained by an individual, as such issues would require professional medical attention. The Company's scientific team keeps abreast of research developments in the area of natural solutions, and will monitor reports of negative impacts of particular natural solutions. Company products will be adjusted where such monitoring reveals new information.
	<i>iii. actions to manage actual and potential positive impacts.</i>	The Company's scientific team keeps abreast of research developments in the area of natural solutions, and will monitor reports of positive impacts of particular natural solutions.
3.3 (e)	<i>Report the following information about tracking the effectiveness of the actions taken:</i>	
	<i>i. processes used to track the effectiveness of the actions;</i>	The Company has not yet implemented processes to track the effectiveness of actions for health impacts.
	<i>ii. goals, targets, and indicators used to evaluate progress;</i>	Goals, targets and indicators regarding the effectiveness of actions for health impacts were not set for the Company's inaugural year as a benefit corporation.
	<i>iii. the effectiveness of the actions, including progress toward the goals and targets;</i>	Not applicable as at the end of the financial year ended December 31, 2022.
	<i>iv. lessons learned and how these have been incorporated into the organization's operational policies and procedures.</i>	Not applicable as at the end of the financial year ended December 31, 2022.

Disclosure Requirements		Response
3.3 (f)	<i>Describe how engagement with stakeholders has informed the actions taken and how it has informed whether the actions have been effective.</i>	The Company has consulted its clinic partner, Psy Integrated Health, on a regular basis in order to have the products reviewed by a multi-disciplinary team of medical doctors, naturopaths and clinical counsellors. Such consultations have resulted in wording changes made within the products.
GRI 416: Customer Health and Safety 2016		
416-1	<i>Percentage of significant product and service categories for which health and safety impacts are assessed for improvement.</i>	100% of our products (Nara, Mindleap and MUJN) are assessed for improvement, given the potential for the health related information distributed through our products to cause harm to the health of our customers.
416-2	<i>Total number of incidents of non-compliance with regulations and/or voluntary codes concerning the health and safety impacts of products and services within the reporting period.</i>	None.

APPROVAL BY THE BOARD OF DIRECTORS

The undersigned, a director of PanGenomic Health Inc., hereby confirms that this Report was approved by the Board of Directors of the Company on March 21, 2023.

BY ORDER OF THE BOARD OF DIRECTORS OF
PANGENOMIC HEALTH INC.

“Robert Nygren”

Robert Nygren

Executive Chair

PanGenomic Health Inc.